Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 808 results for "Ibrutinib"

FDA Expands Use of Imbruvica for Form of Leukemia

By Scott Roberts, HealthDay Reporter MONDAY, July 28, 2014 (HealthDay News) -- Approved use for Imbruvica (ibrutinib) has been expanded to include people with chronic lymphocytic leukemia (CLL) who have a deletion in chromosome 17, the U.S. Food ... US News & World Report, 1 day ago
Imbruvica expands label Seeking Alpha, 1 day ago
FDA Approves Imbruvica for Treating Chromosome 17-Deletion CLL Patients American Journal of Managed Care, 1 day ago

21 images for Ibrutinib

SearchBug, 1 day ago
Drug Discovery and Development, 16 hours ago
OncLive, 1 day ago
Scottrade, 1 day ago, 1 month ago
MedIndia, 1 month ago
Med India, 1 month ago
Capital Bay, 1 month ago
Scottrade, 1 month ago
I Stock Analyst, 1 month ago

Ibrutinib in CLL: Indication Expanded, Benefit Confirmed

Ibrutinib ( Imbruvica , Pharmacyclics), hailed as a " turning point " in the treatment for chronic lymphocytic leukemia (CLL), has just had another indication and a label change approved by the US Food and Drug Administration (FDA). Ibrutinib was ...
 Medscape1 day ago Ibrutinib and Idelalisib Coming to Europe Soon  Diabetes Care4 days ago Ibrutinib, Star in CLL, Subject to Lowly Drug Resistance  General Medicine eJournal1 month ago Ibrutinib Improves CLL Survival and the Praise Flows  Diabetes Care1 month ago

Pharmacyclics/Johnson & Johnson Drug Backed for EU Approval

The EU approval of Pharmacyclics ( PCYC ) and partner Johnson & Johnson's ( JNJ ) oncology drug Imbruvica (ibrutinib) appears well on track with the European Medicines Agency's ( EMA.TO ) Committee for Medicinal Products for Human Use ( CHMP ) ...
 Yahoo! Finance1 day ago FDA expands approval for Johnson & Johnson, Pharmacyclics' Imbruvica in CLL  FirstWord Pharma1 day ago PharmacyclicsJJs ibrutinib could revolutionise CLL  Big News Network1 month ago
Pharmaceutical Business Review

Pending EC decision: Imbruvica, Ibrutinib, Opinion date: 24-Jul-2014

the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Imbruvica 140 mg hard capsule intended for the treatment of relapsed or refractory ...
 European Medicines Agency4 days ago European Medicines Agency Recommends Approval of Two New Treatment Options for Rare Cancers  PharmaAsia1 day ago CHMP recommends Pharmacyclics Imbruvica to treat two blood cancers  Pharmaceutical Technology1 day ago EMA's CHMP backs approval of two new treatment options for rare cancers26-07-2014  Pharma Letter2 days ago

EMA recomienda la aprobación de IMBRUVICA para el tratamiento de dos cánceres sanguíneos

-- La Agencia Europea del Medicamento(EMA) emite una opinión positiva, recomendando la aprobación de IMBRUVICA (ibrutinib) para el tratamiento de dos cánceres sanguíneos SUNNYVALE, California , 26 de julio de 2014 /PRNewswire/ ...
 PR Newswire3 days ago

Ibrutinib mejora la supervivencia en pacientes CLL y SLL: Resultados del estudio RESONATE

En nombre de los investigadores de RESONATE, el doctor Hillmen presentará los resultados del ensayo clínico en fase III en pacientes CLL y SLL. Los pacientes con leucemia linfoide crónica (CLL) o linfoma linfocítico pequeño (SLL) que han ...
 PR Newswire1 month ago L'ibrutinib améliore la survie chez les patients LLC et LPL : résultats de l'étude RESONATE  PR Newswire1 month ago Ibrutinib verbessert Überlebensrate von Patienten mit CLL und SLL: Ergebnisse der RESONATE-Studie  PR Newswire1 month ago Ibrutinib Improves Survival in CLL and SLL Patients: Results From the RESONATE Study  Individual.com1 month ago
Med India

Erratum: Ibrutinib Resistance in Chronic Lymphocytic Leukemia

Ibrutinib Resistance in Chronic Lymphocytic Leukemia ( Correspondence, N Engl J Med 2014 ; 370 : 2352 - 2354 ) . In the list of authors (page 2354), Mr. Perez's first name should have been Alexendar, rather than Alijandro. The article ...
 New England Journal of Medicine1 month ago Ohio State University Wexner Medical Center: Mechanisms of ibrutinib resistance identified in chronic lymphocytic leukemia  NewsRX1 month ago Orphan designation: Ibrutinib for the treatment of treatment of lymphoplasmacytic lymphoma, for the: Treatment of lymphoplasmacytic lymphoma  European Medicines Agency1 month ago Mechanisms of Ibrutinib Resistance Identified in the Treatment of Chronic Lymphocytic Leukemia  Med India1 month ago
Pharma Letter

FDA gives full approval to ibrutinib for CLL

The Food and Drug Administration has given full approval for ibrutinib (Imbruvica) for patients with chronic lymphocytic leukemia who have received at least one prior therapy and for those who
 Oncology Report1 day ago IMBRUVICA® (ibrutinib) Receives Regular Approval by U.S. FDA in Chronic Lymphocytic Leukemia (CLL) and CLL patients with del 17p  Financial Content1 day ago L'Agence européenne des médicaments (EMA) publie un avis positif, recommande l'homologation de l'IMBRUVICA (ibrutinib) pour le traitement de deux cancers du sang  BioMedReports3 days ago Positive Beurteilung der Europäischen Arzneimittel-Agentur: empfiehlt Zulassung von IMBRUVICA (Ibrutinib) zur Behandlung zweier Blutkrebsformen  BioMedReports3 days ago

Ibrutinib Results RESONATE in Refractory CLL

Bruce D. Cheson, MD: Hello. I am Bruce Cheson, Deputy Chief of Hematology/Oncology and Head of Hematology at Georgetown University Hospital and the Lombardi Comprehensive Cancer Center in Washington, DC. Welcome to this edition of Medscape Oncology ...
 General Medicine eJournal1 month ago
Capital Bay

Drug hailed as breakthrough in leukaemia treatment

Ibrutinib was developed with the assistance of scientists at the Royal College of Surgeons in Ireland An international trial of a new drug for the treatment of the most common form of leukaemia has found it increases survival rates and leads to ...
 RTE Online1 month ago New cancer drug Ibrutinib boosts survival rate to 90%  Capital Bay1 month ago Could this be the end of chemotherapy? New leukaemia drug boosts survival rate to 90% and could eventually replace invasive chemical treatment  Capital Bay1 month ago Clinical trials prove new leukaemia drug boosts survival rate to 90%  Irish Medical Times1 month ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less